Stockscreener 앱 받기
31.32
4.72%
-1.55
시간 외 거래:
32.81
1.49
+4.76%
전일 마감가:
$32.87
열려 있는:
$31.92
하루 거래량:
2.38M
Relative Volume:
1.77
시가총액:
$5.82B
수익:
$29.52M
순이익/손실:
$-567.06M
주가수익비율:
-8.5574
EPS:
-3.66
순현금흐름:
$-551.11M
1주 성능:
-16.14%
1개월 성능:
-17.49%
6개월 성능:
-33.81%
1년 성능:
+3.92%
1일 변동 폭
$30.94
$33.02
1주일 범위
$30.94
$36.77
52주 변동 폭
$29.55
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
415-766-3638
주소
700 SAGINAW DR, REDWOOD CITY, CA
RVMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
31.32 | 5.82B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
When the Price of (RVMD) Talks, People Listen - news.stocktradersdaily.com
Revolution Medicines to Deliver Multiple Presentations at - GlobeNewswire
Groundbreaking Lung Cancer Drug Data Revealed: Revolution Medicines' First Clinical Results - Stock Titan
Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now - MSN
Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums - Stock Titan
Revolution Medicines to Participate in April 2025 Investor Conferences - The Manila Times
RVMDRevolution Medicines, Inc. Latest Stock News & Market Updates - Stock Titan
Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock By Investing.com - Investing.com South Africa
Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock - Investing.com
Revolution Medicines executive sells shares worth $128,598 By Investing.com - Investing.com Australia
Revolution Medicines’ general counsel sells $56,920 in stock By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark Goldsmith sells $458,255 in stock By Investing.com - Investing.com Australia
Revolution Medicines CFO Jack Anders sells $72,771 in stock By Investing.com - Investing.com Canada
Revolution Medicines’ general counsel sells $56,920 in stock - Investing.com India
Revolution Medicines CFO Jack Anders sells $72,771 in stock - Investing.com
Revolution Medicines Executives Sell Shares - TradingView
Revolution Medicines CEO Mark Goldsmith sells $458,255 in stock - Investing.com
Revolution Medicines Inc (RVMD) Should Be Considered For The Next Few Weeks - Stocks Register
Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 20 - GuruFocus.com
Revolution Medicines at Leerink Conference: Expanding RAS Inhibitor Reach By Investing.com - Investing.com Canada
Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com Canada
Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa
Revolution Medicines at Barclays Conference: Focus on Pancreatic Cancer Trials - Investing.com UK
Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs - TipRanks
HC Wainwright Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - Defense World
Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now - Yahoo Finance
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Revolution Medicines’ (RVMD) “Outperform” Rating Reiterated at Wedbush - Armenian Reporter
Long Term Trading Analysis for (RVMD) - Stock Traders Daily
Wedbush Reaffirms Outperform Rating for Revolution Medicines (NASDAQ:RVMD) - Defense World
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Revolution stock price target cut to $59 at Needham - Investing.com
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Revolution Medicines Reports 2024 Financial Results and Progress - TipRanks
Earnings call transcript: Revolution Medicines Q4 2024 reflects strategic advancements - Investing.com India
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress - GlobeNewswire
Revolution Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Revolution Medicines Q4 Net Loss Narrows -February 26, 2025 at 05:13 pm EST - Marketscreener.com
Earnings Flash (RVMD) Revolution Medicines Q4 Loss of $1.12 per Share vs. FactSet Est Loss of $0.99 - Marketscreener.com
Revolution Medicines, Inc. SEC 10-K Report - TradingView
Can Revolution Medicines' $2.3B War Chest Overcome Mounting Losses in Cancer Drug Race? - StockTitan
Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 2024 Result - Yahoo Finance
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):